# antibodies -online.com





# anti-FLT3 antibody (FITC)

**Images** 



Publication



( )	11/0	r\ /1	$\triangle 1 $
	$\lor \lor \vdash$	$I \vee I$	ew

0 111	100	
Quantity:	100 tests	
Target:	FLT3	
Reactivity:	Human	
Host:	Mouse	
Clonality:	Monoclonal	
Conjugate:	This FLT3 antibody is conjugated to FITC	
Application:	Flow Cytometry (FACS)	

Product Details		
Immunogen:	BV-173 leukemic cell line	
Clone:	BV10A4	
Isotype:	lgG1	
Specificity:	The mouse monoclonal antibody BV10A4 (BV10) reacts with an extracellular epitope of CD135 (FLT3, FLK2, STK-1), a 130-160 kDa type I transmembrane receptor tyrosine kinase that is involved in early steps of hematopoiesis.	
No Cross-Reactivity:	Mouse	
Cross-Reactivity (Details):	Human	
Purification:	Purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.	


# **Target Details**

Target:	FLT3	
Alternative Name:	CD135 (FLT3 Products)	
Background:	Fms related tyrosine kinase 3,CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of Box cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well	
	as on various malignant hematopoietic cells.,FLT3, FLK2, STK1	
Gene ID:	2322	
UniProt:	P36888	
Pathways:	RTK Signaling	
Application Details		
Application Notes:	Flow cytometry: The reagent is designed for analysis of human blood cells using 4 $\mu$ L reagent / 100 $\mu$ L of whole blood or 10 <sup>6</sup> cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.	
Comment:	The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.	
Restrictions:	For Research Use only	
Handling		
Buffer:	Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide	
Preservative:	Sodium azide	
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.	
Storage:	4 °C	
Storage Comment:	Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.	

Product cited in:


Haylock, Horsfall, Dowse, Ramshaw, Niutta, Protopsaltis, Peng, Burrell, Rappold, Buhring, Simmons: "Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand." in: **Blood**, Vol. 90, Issue 6, pp. 2260-72, (1997) (PubMed).

## **Images**



## **Flow Cytometry**

**Image 1.** Flow cytometry surface staining pattern of REH cellular suspension stained using anti-human CD135 (BV10A4) FITC antibody (4  $\mu$ L reagent per million cells in 100  $\mu$ L of cell suspension).



#### **Flow Cytometry**

**Image 2.** Separation of REH cells stained using anti-human CD135 (BV10A4) FITC antibody (4  $\mu$ L reagent per million cells in 100  $\mu$ L of cell suspension, red-filled) from REH cells unstained by primary antibody (black-dashed) in flow cytometry analysis (surface staining).